Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Isoflurane + analgesic drug refers to the combination of the inhalational general anesthetic isoflurane with an additional analgesic agent, typically used in both human and veterinary medicine to achieve balanced anesthesia. Isoflurane acts as a volatile anesthetic for induction and maintenance of general anesthesia by enhancing inhibitory neurotransmission (notably via GABA receptors) and reducing neuronal excitability. Analgesic drugs co-administered may include opioids (such as butorphanol or buprenorphine), alpha-2 agonists (such as xylazine or medetomidine), or other agents like ketamine, which provide pain relief and can reduce the required dose of isoflurane, improving cardiorespiratory stability during procedures[3][5][7]. The combination aims to optimize anesthesia depth while minimizing side effects such as respiratory depression.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on isoflurane + analgesic drug.